What it is

Dual GIP and GLP-1 receptor agonist used in metabolic-signaling research.

Also known as

GLP-2 TRZ · Dual GIP/GLP-1 agonist · Mounjaro/Zepbound analog (research context)

Overview

Tirzepatide is a dual agonist at the GIP and GLP-1 receptors and is widely used as a reference ligand in metabolic and incretin-pathway research. Literature covers glycemic signaling, appetite-related endpoints, and body-composition measures in both clinical-development and preclinical contexts.

Research catalogs carry it for head-to-head and mechanism studies against single GLP-1 agonists. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• Dual GIP/GLP-1 receptor engagement endpoints

• • Glycemic and insulin-sensitivity markers in metabolic models

• • Appetite and satiety-pathway readouts

• • Body-composition and weight-change endpoints where studied

• • Comparative incretin pharmacology versus mono-agonists

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early receptor-engagement and appetite/energy-signaling readouts in model systems; compound exposure establishing.

• • Week 3–4: Clearer metabolic and satiety-pathway markers in short preclinical windows.

• • Month 2–3: More stable body-composition and glucose/lipid-related endpoints where studied.

• • Month 3–6: Sustained metabolic-signaling observations in longer research designs.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.